BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors
BRIEF-Oncolytics Biotech Reports Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Pelareorep Combined With Car T Cell Therapy In Solid Tumors
Feb 23 (Reuters) - Oncolytics Biotech Inc ONC.TO :
路透2月23日电-Oncolytics Biotech Inc.ONC.TO:
* ONCOLYTICS BIOTECH REPORTS PRECLINICAL DATA DEMONSTRATING SYNERGISTIC ANTI-CANCER ACTIVITY OF PELAREOREP COMBINED WITH CAR T CELL THERAPY IN SOLID TUMORS
*Oncolytics生物技术报告临床前数据显示,Pelareorep联合CAR T细胞治疗在实体瘤中具有协同抗癌活性
* ONCOLYTICS BIOTECH INC - MAYO CLINIC SHOWS PELAREOREP VASTLY IMPROVED PERSISTENCE AND EFFICACY OF CAR T CELL THERAPY LEADING TO CURES IN MODEL
*Oncolytics Biotech Inc-Mayo诊所显示,Pelareorep极大地提高了CAR T细胞治疗的持久性和有效性,从而治愈了In模型
* ONCOLYTICS BIOTECH INC - PELAREOREP&aposS SYNERGISTIC EFFECTS WITH CAR T THERAPY APPEAR TO BE SPECIFIC AND WERE NOT OBSERVED WITH ONCOLYTIC VIRUS VSV
*Oncolytics Biotech Inc-pelareorep&aposS与CAR T治疗的协同效应似乎是特异的,在溶瘤病毒VSV中没有观察到
* ONCOLYTICS BIOTECH INC - RESULTS DEMONSTRATE POTENTIAL OF PELAREOREP TO BROADEN APPLICABILITY OF CAR T CELLS TO SOLID TUMORS
*Oncolytics Biotech Inc-结果表明,Pelareorep有潜力扩大CAR T细胞对实体肿瘤的适用性
Source text for Eikon: Further company coverage:
Eikon的源文本:进一步的公司报道:
译文内容由第三方软件翻译。